title: Impact of acute gain on clinical outcomes of patients treated with sirolimus-eluting stent. - A sub-analysis study from the STLLR trial-.
abstract: BACKGROUND
  Geographical miss (GM), representing suboptimal drug-eluting stent deployment, is associated with an increased risk of target lesion revascularization (TLR) and myocardial infarction. The impact of suboptimal stenting techniques on clinical outcomes in diabetics remains unknown.
  
  
  RESULTS
  Stent deployment Techniques on cLinicaL outcomes of patients treated with the cypheR(TM) stent (STLLR) is the first multicenter, large trial to prospectively evaluate outcomes associated with sirolimus-eluting stent (SES) deployment techniques. Axial GM and longitudinal GM (LGM), defined as a balloon injured segment or a diseased segment not covered by a SES, were assessed by an independent core laboratory. One-year outcomes between diabetics and non-diabetics and their relationship with GM were assessed. This substudy included 1,336 patients, 28.8% with diabetes. In non-LGM patients, TLR was similarly low in both diabetics and non-diabetics (2.0% vs. 2.0%, P=NS). However, TLR increased 4.1 times in diabetics (8.0%) and 1.9 times in non-diabetics (3.8%) in the presence of LGM (P=0.03). Axial GM had no impact on outcomes. By univariate analysis, stent length, acute gain, and LGM were the predictors of TLR in the total cohort. However, by multivariate analysis, acute gain was the only predictor of TLR (P=0.03), independently of LGM or diabetes.
  
  
  CONCLUSIONS
  Acute gain is the exclusive predictor of TLR after SES implantation. Particularly in diabetics, the negative impact of LGM on TLR seems to be amplified. Diligent SES deployment for larger acute gain is critical to improve clinical outcomes.
authors.affiliation: Harrington McLaughlin Heart and Vascular Institute, University Hospitals Case Medical Center, and Case Western Reserve University, Cleveland, OH, USA.
authors.forename: Satoko
authors.initials: S
authors.lastname: Tahara
authors.forename: Hiram G
authors.initials: HG
authors.lastname: Bezerra
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kyono
authors.forename: Thomas
authors.initials: T
authors.lastname: Carrigan
authors.forename: Emile
authors.initials: E
authors.lastname: Mehanna
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Marco A
authors.initials: MA
authors.lastname: Costa
mesh_terms: D048909:Diabetes Complications / Q000453:epidemiology / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000628:therapy*; D011446:Prospective Studies; D020123:Sirolimus / Q000009:adverse effects* / Q000494:pharmacology
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus